StockData
Gilead Sciences, Inc. logo

Gilead Sciences, Inc. (GILD) stock

GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 30, 2026Score 12/30104% above fair value
$170.26+2.68 (+1.60%)

Close on Nov 17, 2026Market cap $211.18BP/E –Yield 1.86%

Gilead Sciences price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Gilead Sciences's price to book ratio was 17.8× on Nov 11, 2026, against 7.3× a year earlier. Over the last 5 years it ranged from 3.5× to 17.9×, with a median of 5.2×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202617.8×+10.7
2025Dec 31, 20257.1×+0.8
2024Dec 31, 20246.2×+1.7
2023Dec 29, 20234.5×−0.6
2022Dec 30, 20225.1×+0.9
2021Dec 31, 20214.2×+0.1
2020Dec 31, 20204.2×+0.2
2019Dec 31, 20194.0×+0.5
2018Dec 31, 20183.5×−0.2
2017Dec 29, 20173.8×−1.8
2016Dec 30, 20165.6×−2.8
2015Dec 31, 20158.4×−2.1
2014Dec 31, 201410.5×−0.1
2013Dec 31, 201310.6×+4.1
2012Dec 31, 20126.5×+1.4
2011Dec 30, 20115.1×−0.1
2010Dec 31, 20105.2×−1.7
2009Dec 31, 20096.9×–

More Gilead Sciences figures

See a number that looks wrong?